SeaStar Medical - תחזית צמיחת רווח נקי למניה לשנה הבאה ICU

The pre-revenue stage requires strict cost control, although SeaStar Medical Holding (ICU) management demonstrates high regulatory expertise. The 12-month forward EPS trajectory clearly captures these expectations, with the metric holding around 38.30. The innovative blood purification method for inflammation assists with organ failure, while modernized cartridge production facilities ensure a stable manufacturing cycle.
ICU (SeaStar Medical): פילוחים אנליטיים ודוחות לפי אינדיקטורים

For SeaStar Medical (ICU), whose valuation is based on R&D potential in treating systemic inflammation, the trend in expected earnings reflects market confidence in the commercialization of its technologies. This projected growth in net income per share for the coming year measures the average analyst consensus forecast, capturing daily adjustments to future revenues relative to current performance. The downward trend on this chart warns of a capital overvaluation, even if the company's mission remains relevant.